- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Kylin To Use Its pRNA Technology to Help Develop New RNAi Therapeutics to Treat Cancer
Kylin Therapeutics, Inc., a biotechnology company, announced it has signed a collaboration with Fort Dodge Animal Health, a division of Wyeth (NYSE:WYE), to develop new RNAi therapeutics for the treatment of cancer. Under the terms of the three-year contract, Kylin will receive research funding, milestone payments and royalties.
Under this contract, Kylin will use its patented RNA nanoparticle technology called "pRNA" to explore the enormous potential of RNA interference (RNAi) and develop new RNA-based therapeutics for the treatment of cancer. In return for its participation in this effort, Fort Dodge will receive an exclusive license to the pRNA/RNAi therapeutic compounds for the treatment of cancers in companion animals. Kylin will retain rights to the therapies for human use.
"We are delighted to welcome Fort Dodge/Wyeth as Kylin's partner. Our business models are complementary, and the results of this effort will provide valuable data and intellectual property that will mutually serve our core businesses," said J. Eric Davis, J.D., president and CEO of Kylin Therapeutics.
The pRNA technology was developed by Peixuan Guo at Purdue University.
About Kylin Therapeutics, Inc.
About Kylin Therapeutics
Kylin ( http://www.kylintherapeutics.com ), which is based at the Purdue Research Park, is a leading biotechnology company focused on delivery and development of RNAi based therapeutics. The company employs its revolutionary RNA nanotechnology platform called "pRNA" to develop the potential of RNA interference (RNAi) to treat many common diseases. Kylin's technology platform has the potential to meet the growing market for treating cancer, HIV and other diseases with RNA-based therapeutics.
About Fort Dodge/Wyeth
Fort Dodge Animal Health is a leading manufacturer and distributor of animal health products for the livestock, companion animal, equine, swine and poultry industries in North America and international markets. Key products include CYDECTIN® Pour-On, QUEST® Gel, the Duramune and Fel-O-Vax® vaccine lines, and West-Nile Innovator® equine vaccines. Fort Dodge is headquartered in Overland Park, Kan.
For more information, please click here
Purdue Research Foundation
Marketing and Communication Contact:
Cynthia Sequin, 765-494-4192 (office)
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Researchers develop new way to manufacture nanofibers May 21st, 2015
Effective Nano-Micelles Designed in Iran to Treat Cancer May 20th, 2015
Haydale Named Lead Sponsor for Cambridge Graphene Festival May 22nd, 2015
DiATOME enables surface preparation for AFM and FIB May 19th, 2015
Efficiency record for black silicon solar cells jumps to 22.1 percent: Aalto University's researchers improved their previous record by over 3 absolute percents in cooperation with Universitat Politècnica de Catalunya May 18th, 2015
Organic nanoparticles, more lethal to tumors: Carbon-based nanoparticles could be used to sensitize cancerous tumors to proton radiotherapy and induce more focused destruction of cancer cells, a new study shows May 18th, 2015